These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9156935)

  • 41. Assessments of clinical trials of charcoal hemoperfusion in uremic patients.
    Chang TM
    Clin Nephrol; 1979 Feb; 11(2):111-9. PubMed ID: 378489
    [No Abstract]   [Full Text] [Related]  

  • 42. The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients.
    Brophy DF; Martin EJ; Carr SL; Kirschbaum B; Carr ME
    Thromb Res; 2007; 119(6):723-9. PubMed ID: 16793120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The first 15 minutes of hemodialysis does not affect platelets.
    Komarnicki M; Kaźmierczak M; de Mezer-Dambek M
    Haematologia (Budap); 1996; 28(1):41-4. PubMed ID: 9283903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of platelet aggregation disturbances and their relation to treatment in patients with chronic uremia.
    Komarnicki M; Pietrzak I
    Int J Artif Organs; 1988 Mar; 11(2):91-4. PubMed ID: 3131259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perfusion of uremic blood ultrafiltrate on uncoated charcoal.
    Politi L; Cerulli N; D'Angelo AR; Scandurra R
    Artif Organs; 1989 Jun; 13(3):246-51. PubMed ID: 2764765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blood level of middle molecular substances during uraemia and haemodialysis.
    Dzúrik R; Bozek P; Reznícek J; Oborníková A
    Proc Eur Dial Transplant Assoc; 1973; 10(0):263-70. PubMed ID: 4802412
    [No Abstract]   [Full Text] [Related]  

  • 47. Uremia and thrombotic microangiopathy: conditions that may havethe same manifestation.
    Gao J; Zhou L; Wei J; Gao Y; Pan P; Sun Q; Na Y
    Ren Fail; 2013; 35(2):286-8. PubMed ID: 23362978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma phospholipids and platelet function in uremic patients.
    Vecino A; Teruel JL; Navarro JL; Cesar JM
    Am J Nephrol; 1996; 16(5):409-11. PubMed ID: 8886178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The beginning of repeated hemodialysis treatment enhances some platelet functions in uremic patients.
    Krawczyk W; Dmoszýnska A; Marczewski K
    Nephron; 1995; 71(3):361-2. PubMed ID: 8569990
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
    Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
    Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Uremic polyneuritis. Significance of determination of neural conduction velocity (NCV) and level of mean molecules (MM)].
    El Matri A; Ben Dridi M; Belkahia C; Ben Abdallah T; Crevat A; Ben Maiz H; Ben Ayed H
    Tunis Med; 1979; 57(6):348-51. PubMed ID: 555111
    [No Abstract]   [Full Text] [Related]  

  • 52. Requirement of hemofiltration (HF) in uremic patients.
    Civati G; Guastoni C; Perego A; Teatini U; Minetti L
    Life Support Syst; 1983; 1 Suppl 1():282-8. PubMed ID: 6336430
    [No Abstract]   [Full Text] [Related]  

  • 53. [Middle molecules separation from uraemic serum (author's transl)].
    Dall'aglio P; Buzio C; Gardini GP; Migone L
    Ateneo Parmense Acta Biomed; 1975; 46(5):331-44. PubMed ID: 1236694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis.
    Matsuo T; Kobayashi H; Matsuo M; Wanaka K; Nakamoto H; Matsushima H; Sakai R
    Pathophysiol Haemost Thromb; 2006; 35(6):445-50. PubMed ID: 17565238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of bleeding in dialysis patients.
    Galbusera M; Remuzzi G; Boccardo P
    Semin Dial; 2009; 22(3):279-86. PubMed ID: 19573008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The blood platelet proteome is changed in UREMIC patients.
    Walkowiak B; Kaminska M; Okrój W; Tanski W; Sobol A; Zbróg Z; Przybyszewska-Doros I
    Platelets; 2007 Aug; 18(5):386-8. PubMed ID: 17654309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of erythropoietin therapy and selenium supplementation on selected antioxidant parameters in blood of uremic patients on long-term hemodialysis.
    Adamowicz A; Trafikowska U; Trafikowska A; Zachara B; Manitius J
    Med Sci Monit; 2002 Mar; 8(3):CR202-5. PubMed ID: 11887037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Assessment of haemostasis in fifteen uraemic patients subjected to chronic haemodialysis (author's transl)].
    Barrantes Boulanger A; Soto Quirós M; Salas González R
    Sangre (Barc); 1980; 25(3):289-99. PubMed ID: 7414445
    [No Abstract]   [Full Text] [Related]  

  • 59. Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat.
    Anderstam B; Mamoun AH; Södersten P; Bergström J
    J Am Soc Nephrol; 1996 Nov; 7(11):2453-60. PubMed ID: 8959639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Limited value of zinc protoporphyrin as a marker of iron status in chronic hemodialysis patients.
    Canavese C; Grill A; Decostanzi E; Maddalena E; Barbieri S; Martina G; Fop F; Buglione E; Grechi D; David O; Saitta M; Piccoli G
    Clin Nephrol; 2000 Jan; 53(1):42-7. PubMed ID: 10661481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.